Cold-induced Brown Fat Activation and Hepatic Steatosis
- Sponsor
- Medical University of Vienna
- Study ID
- NCT03811236
- Status
- Recruiting
Conditions
- Non-Alcoholic Fatty Liver Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cold exposure — OTHERTwo hours of mild cold exposure using a water-perfused vest
Study Details
In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype. Longitudinal studies which applied recurrent cooling sessions demonstrated a high plasticity of BAT which significantly increased in size and activity during these studies. These changes were accompanied by improvements in body fat mass as well as insulin sensitivity. Non-alcoholic fatty liver disease (NAFLD) is estimated to advance to the primary cause of liver cirrhosis and hepatocellular carcinoma in the following years. Besides predisposing genetic and possibly nutritional factors, the insulin resistance syndrome and obesity are the main factors contributing to this excessive hepatic lipid accumulation. The aim of this study is to investigate whether BAT recruitment via cold-acclimation results in decreased hepatic lipid content in overweight/obese patients with NAFLD.
Key Dates
- First listed
- Jan 22, 2019
- Start date
- Jan 21, 2019
- Status verified
- Mar 2024
- Primary completion
- Dec 31, 2025
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 26 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Cold exposure
- No Intervention: Room temperature
Primary Outcome Measure
Hepatic lipid content (%) [ Time Frame: Six weeks ]
Central Contacts
- Florian Kiefer, MD, PhD+43140400
Related Studies
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseasePHASE2 · Not Yet Recruiting · Justin Ryder · Chicago, Illinois
- Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- The Olmsted NAFLD Epidemiology Study (TONES)Recruiting · Mayo Clinic · Rochester, Minnesota
- AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)Recruiting · AdventHealth Translational Research Institute · Orlando, Florida